top of page


7 NEAT ID Integration Grants have been awarded. NEAT ID have also supported junior doctors travelling to global conferences and provided grants supporting panel meetings. 3 grants have been awarded at the end of 2022 and expect to begin in 2023. 

What is a NEAT ID Integration Grant? 

  • A scientific grant given to a minimum of two countries in collaboration, which includes at least one NEAT ID site.

  • They are preferentially provided to studies which may relate to ongoing NEAT ID trials

  • Cover a wide range of infectious diseases which NEAT ID are interested in, HIV, Hepatitis, MPX, COVID  

  • The value of the grant is around 100,000 euros 

  • Reviewed by an independent international panel of experts 

2022 NEAT ID Integration Grants 

Dr Merle Henderson 

Imperial College London

Title: Longitudinal changes in plasma neuronal markers in persons with HIV commencing ART.

Dr Linos Vandekerckhove 

Ghent university

Title: Feasibility evaluation of anti-HIV Antibody-secreting Chimeric Antigen Receptor T cells as a potential cure in acute seroconverters

Dr Christoph Boesecke

Bonn University Hospital

Title: NEAT-No-C: A multicenter European cohort on annual HCV incidence in MSM in Europe with an embedded European HCV biobank

2018 NEAT ID Integration Grant

Professor Charles Béguelin Grant 2018

Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland

Kinetics of Hepatitis B Virus markers in treated HIV/HBV-coinfected patients


  1. Begré L, Béguelin C, Boyd A, Peters L, Rockstroh J, Günthard HF, Bernasconi E, Cavassini M, Lacombe K, Mocroft A, Wandeler G, Rauch A. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection. Front Med (Lausanne). 2022 Sep 15;9:988356. IF 4.71

  2. Eveline Hofmann, Bernard Surial, Noémie Boillat-Blanco, Huldrych F Günthard, Marcel Stöckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch, Gilles Wandeler, Charles Béguelin, for the Swiss HIV Cohort Study. Clinical Infectious Diseases. 2023 Feb. 10.1093/cid/ciac823


2016 NEAT ID Integration Grant

Dr Christoph Boeseck Grant 2016

Bonn University Hospital  NEAT 001 Follow Up 

Re-infection and DAA-based treatment uptake in acute HCV coinfection within the European acute HCV cohort PROBE-C


  1. Published in Clinical Infectious Diseases. “Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus–Positive Men Who Have Sex With Men (PROBE-C Study)”

Using Partial Data: 

 2. Published In Clinical Infectious Diseases. “Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After        Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era” 

Has been awarded NEAT ID Integration Grant 2022 for follow up.

Dr Jose Arribas Grant 2016

Foundation for Biomedical Research of University, Hospital La Paz, Madrid 

Telomere length changes after darunavir-ritonavir combined with either raltegravir or tenofovir- emtricitabine in antiretroviral-naive adults with HIV-1: a sub-study of the NEAT001/ANRS143 



  1. Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. J Infect Dis. 2018 Oct 5;218(10):1523-1530. IF 5.60

  2. Alejos B, Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Schwimmer C, Bernardino JI, Rodes B, Esser S, Goujard C, Sarmento-Castro R, De Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ANRS 143 Study Group. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial. HIV Med. 2019 Nov;20(10):691-698. IF 3.556 


Prof. Gilles Wandeler Grant 2016

University of Bern

Multi-cohort study to inform hepatocellular carcinoma screening strategies in HIV/HBV-coinfected individuals on tenofovir-containing therapy


  1. Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gjærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A; Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. J Hepatol. 2019 Aug;71(2):274-280. IF 30.083

  2. Charles Béguelin, Andrew Atkinson, Anders Boyd, Karolin Falconer, Nikolai Kirkby, Franziska Suter-Riniker, Huldrych F. Günthard, Jürgen K. Rockstroh, Amanda Mocroft, Andri Rauch, Lars Peters, Gilles Wandeler, for EuroSIDA and SHCS. Liver International. January 2023 10.1111/liv.15519

bottom of page